These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28869324)

  • 1. Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs.
    Varnell CD; Fukuda T; Kirby CL; Martin LJ; Warshaw BL; Patel HP; Chand DH; Barletta GM; Van Why SK; VanDeVoorde RG; Weaver DJ; Wilson A; Verghese PS; Vinks AA; Greenbaum LA; Goebel J; Hooper DK
    Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28869324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients.
    Ohmann EL; Burckart GJ; Brooks MM; Chen Y; Pravica V; Girnita DM; Zeevi A; Webber SA
    J Heart Lung Transplant; 2010 May; 29(5):509-16. PubMed ID: 20061166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil.
    Brum S; Nolasco F; Sousa J; Ferreira A; Possante M; Pinto JR; Barroso E; Santos JR
    Transplant Proc; 2008 Apr; 40(3):752-4. PubMed ID: 18455007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
    Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus: a switch option for mycophenolate mofetil-induced leukopenia in renal transplant recipients.
    Shin BC; Chung JH; Kim HL
    Transplant Proc; 2013 Oct; 45(8):2968-9. PubMed ID: 24157014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.
    Moreso F; Serón D; Morales JM; Cruzado JM; Gil-Vernet S; Pérez JL; Fulladosa X; Andrés A; Grinyó JM
    Clin Transplant; 1998 Jun; 12(3):198-205. PubMed ID: 9642510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.
    Jacobson PA; Schladt D; Oetting WS; Leduc R; Guan W; Matas AJ; Lamba V; Mannon RB; Julian BA; Israni A;
    Transplantation; 2011 Feb; 91(3):309-16. PubMed ID: 21107304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil.
    Molina Perez E; Fernández Castroagudín J; Seijo Ríos S; Mera Calviño J; Tomé Martínez de Rituerto S; Otero Antón E; Bustamante Montalvo M; Varo Perez E
    Transplant Proc; 2009 Apr; 41(3):1047-9. PubMed ID: 19376423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients.
    Prausa SE; Fukuda T; Maseck D; Curtsinger KL; Liu C; Zhang K; Nick TG; Sherbotie JR; Ellis EN; Goebel J; Vinks AA
    Clin Pharmacol Ther; 2009 May; 85(5):495-500. PubMed ID: 19225446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inosine 5'-monophosphate dehydrogenase 1 haplotypes and association with mycophenolate mofetil gastrointestinal intolerance in pediatric heart transplant patients.
    Ohmann EL; Burckart GJ; Chen Y; Pravica V; Brooks MM; Zeevi A; Webber SA
    Pediatr Transplant; 2010 Nov; 14(7):891-5. PubMed ID: 20649757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
    Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mycophenolate mofetil].
    Abramowicz D; Broeders N; Wissing M; Sternon J
    Rev Med Brux; 1998 Jun; 19(3):139-43. PubMed ID: 9697397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.
    Vanhove T; Kuypers D; Claes KJ; Evenepoel P; Meijers B; Naesens M; Vanrenterghem Y; Cornelis T; Bammens B
    Transpl Int; 2013 Aug; 26(8):813-21. PubMed ID: 23746202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia.
    Hao C; Anwei M; Bing C; Baiyong S; Weixia Z; Chuan S; Erzhen C; Xiaxing D; Weihua Q; Weiping Y; Chenghong P; Hongwei L
    Liver Transpl; 2008 Aug; 14(8):1165-73. PubMed ID: 18668650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil in liver transplantation.
    McDiarmid SV
    Clin Transplant; 1996 Feb; 10(1 Pt 2):140-5. PubMed ID: 8680052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malnutrition Risk in Kidney Recipients Treated With Mycophenolate Mofetil Is Associated With IMPDH1 rs2278294 Polymorphism.
    Pazik J; Lewandowski Z; Nowacka Cieciura E; Ołdak M; Podgórska M; Sadowska A; Dęborska Materkowska D; Durlik M
    Transplant Proc; 2018; 50(6):1794-1797. PubMed ID: 30056902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?
    Basic-Jukic N; Kes P; Bubic-Filipi LJ; Puretic Z; Brunetta B; Pasini J
    Transplant Proc; 2005 Mar; 37(2):850-1. PubMed ID: 15848553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients.
    Siddiqi N; Lamour JM; Hsu DT
    Pediatr Transplant; 2015 Sep; 19(6):618-22. PubMed ID: 26082342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients.
    Bunchman T; Navarro M; Broyer M; Sherbotie J; Chavers B; Tönshoff B; Birk P; Lerner G; Lirenman D; Greenbaum L; Walker R; Zimmerhackl LB; Blowey D; Clark G; Ettenger R; Arterburn S; Klamerus K; Fong A; Tang H; Thomas S; Ramos E
    Pediatr Nephrol; 2001 Dec; 16(12):978-84. PubMed ID: 11793083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients.
    Rerolle JP; Szelag JC; Le Meur Y
    Nephrol Dial Transplant; 2007 Feb; 22(2):671-2. PubMed ID: 16980323
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.